blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2970351

EP2970351 - RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS [Right-click to bookmark this link]
Former [2016/03]RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS
[2017/15]
StatusNo opposition filed within time limit
Status updated on  20.07.2018
Database last updated on 02.09.2024
FormerThe patent has been granted
Status updated on  11.08.2017
FormerGrant of patent is intended
Status updated on  23.03.2017
FormerExamination is in progress
Status updated on  24.01.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Translate Bio, Inc.
200 Sidney Street, Suite 310
Cambridge, MA 02139 / US
[2017/35]
Former [2016/47]For all designated states
Shire Human Genetic Therapies, Inc.
300 Shire Way
Lexington MA 02421 / US
Former [2016/03]For all designated states
Shire Human Genetic Therapies, Inc.
300 Shire Way
Lexington, MA 02421 / US
Inventor(s)01 / DEROSA, Frank
c/o SHIRE HUMAN GENETIC THERAPIES INC.
300 Shire Way
Lexington, Massachusetts 02421 / US
02 / HEARTLEIN, Michael
c/o SHIRE HUMAN GENETIC THERAPIES INC.
300 Shire Way
Lexington, Massachusetts 02421 / US
 [2016/03]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2016/03]
Application number, filing date14721635.214.03.2014
[2016/03]
WO2014US27422
Priority number, dateUS201361785098P14.03.2013         Original published format: US 201361785098 P
[2016/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014152513
Date:25.09.2014
Language:EN
[2014/39]
Type: A1 Application with search report 
No.:EP2970351
Date:20.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 25.09.2014 takes the place of the publication of the European patent application.
[2016/03]
Type: B1 Patent specification 
No.:EP2970351
Date:13.09.2017
Language:EN
[2017/37]
Search report(s)International search report - published on:EP25.09.2014
ClassificationIPC:C12N15/67
[2017/16]
CPC:
A61P43/00 (EP); C07H21/02 (US); C12N15/67 (EP,US);
A61K9/1271 (US); A61K9/1272 (US); C12N2310/3515 (US)
Former IPC [2017/15]C12N15/11, C12N15/67
Former IPC [2016/03]C07H5/10, C12N15/11
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/03]
Extension statesBA07.09.2015
ME07.09.2015
TitleGerman:RIBONUKLEINSÄUREN MIT 4'-THIO-MODIFIZIERTEN NUKLEOTIDEN UND ZUGEHÖRIGE VERFAHREN[2016/03]
English:RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS[2017/15]
French:ACIDES RIBONUCLÉIQUES AYANT DES NUCLÉOTIDES 4'-THIO-MODIFIÉS ET PROCÉDÉS ASSOCIÉS[2016/03]
Former [2016/03]RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS
Entry into regional phase07.09.2015National basic fee paid 
07.09.2015Designation fee(s) paid 
07.09.2015Examination fee paid 
Examination procedure07.09.2015Examination requested  [2016/03]
27.04.2016Amendment by applicant (claims and/or description)
13.09.2016Despatch of a communication from the examining division (Time limit: M04)
23.01.2017Reply to a communication from the examining division
24.03.2017Communication of intention to grant the patent
03.08.2017Fee for grant paid
03.08.2017Fee for publishing/printing paid
03.08.2017Receipt of the translation of the claim(s)
Divisional application(s)EP17189627.7  / EP3301102
EP20169380.1
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.09.2016
Opposition(s)14.06.2018No opposition filed within time limit [2018/34]
Fees paidRenewal fee
31.03.2016Renewal fee patent year 03
27.03.2017Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.03.2014
AL13.09.2017
AT13.09.2017
CY13.09.2017
CZ13.09.2017
DK13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
MK13.09.2017
NL13.09.2017
PL13.09.2017
PT13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SI13.09.2017
SK13.09.2017
SM13.09.2017
TR13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
IE14.03.2018
LU14.03.2018
MT14.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
[2020/34]
Former [2020/31]HU14.03.2014
AT13.09.2017
CY13.09.2017
CZ13.09.2017
DK13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
MK13.09.2017
NL13.09.2017
PL13.09.2017
PT13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SI13.09.2017
SK13.09.2017
SM13.09.2017
TR13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
IE14.03.2018
LU14.03.2018
MT14.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
Former [2020/30]HU14.03.2014
AT13.09.2017
CZ13.09.2017
DK13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
NL13.09.2017
PL13.09.2017
PT13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SI13.09.2017
SK13.09.2017
SM13.09.2017
TR13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
IE14.03.2018
LU14.03.2018
MT14.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
Former [2020/28]AT13.09.2017
CZ13.09.2017
DK13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
NL13.09.2017
PL13.09.2017
PT13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SI13.09.2017
SK13.09.2017
SM13.09.2017
TR13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
IE14.03.2018
LU14.03.2018
MT14.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
Former [2020/16]AT13.09.2017
CZ13.09.2017
DK13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
NL13.09.2017
PL13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SI13.09.2017
SK13.09.2017
SM13.09.2017
TR13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
IE14.03.2018
LU14.03.2018
MT14.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
Former [2020/08]AT13.09.2017
CZ13.09.2017
DK13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
NL13.09.2017
PL13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SI13.09.2017
SK13.09.2017
SM13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
IE14.03.2018
LU14.03.2018
MT14.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
Former [2019/12]AT13.09.2017
CZ13.09.2017
DK13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
NL13.09.2017
PL13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SI13.09.2017
SK13.09.2017
SM13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
IE14.03.2018
LU14.03.2018
BE31.03.2018
CH31.03.2018
LI31.03.2018
Former [2019/09]AT13.09.2017
CZ13.09.2017
DK13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
NL13.09.2017
PL13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SI13.09.2017
SK13.09.2017
SM13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
IE14.03.2018
LU14.03.2018
Former [2019/04]AT13.09.2017
CZ13.09.2017
DK13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
NL13.09.2017
PL13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SI13.09.2017
SK13.09.2017
SM13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
LU14.03.2018
Former [2018/52]AT13.09.2017
CZ13.09.2017
DK13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
NL13.09.2017
PL13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SI13.09.2017
SK13.09.2017
SM13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
Former [2018/35]AT13.09.2017
CZ13.09.2017
DK13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
NL13.09.2017
PL13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SK13.09.2017
SM13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
Former [2018/24]AT13.09.2017
CZ13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
NL13.09.2017
PL13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SK13.09.2017
SM13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
Former [2018/23]AT13.09.2017
CZ13.09.2017
EE13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
NL13.09.2017
PL13.09.2017
RO13.09.2017
RS13.09.2017
SE13.09.2017
SK13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
IS13.01.2018
Former [2018/21]CZ13.09.2017
FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
NL13.09.2017
RS13.09.2017
SE13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
Former [2018/15]FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
NL13.09.2017
RS13.09.2017
SE13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
Former [2018/12]FI13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
RS13.09.2017
SE13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
Former [2018/11]FI13.09.2017
HR13.09.2017
LT13.09.2017
RS13.09.2017
SE13.09.2017
BG13.12.2017
NO13.12.2017
GR14.12.2017
Former [2018/09]FI13.09.2017
LT13.09.2017
SE13.09.2017
NO13.12.2017
Former [2018/08]FI13.09.2017
LT13.09.2017
NO13.12.2017
Former [2018/07]LT13.09.2017
NO13.12.2017
Cited inInternational search[AD]  - MICHAEL S D KORMANN ET AL, "Expression of therapeutic proteins after delivery of chemically modified mRNA in mice", NATURE BIOTECHNOLOGY, (20110201), vol. 29, no. 2, doi:10.1038/nbt.1733, ISSN 1087-0156, pages 154 - 157, XP055040839 [AD] 1-29 * the whole document *

DOI:   http://dx.doi.org/10.1038/nbt.1733
 [A]  - B. R. ANDERSON ET AL, "Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L", NUCLEIC ACIDS RESEARCH, (20111101), vol. 39, no. 21, doi:10.1093/nar/gkr586, ISSN 0305-1048, pages 9329 - 9338, XP055126203 [A] 1-29 * the whole document *

DOI:   http://dx.doi.org/10.1093/nar/gkr586
 [AD]  - KARIKÓ KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 16, no. 11, doi:10.1038/MT.2008.200, ISSN 1525-0024, (20081101), pages 1833 - 1840, (20080916), XP002598556 [AD] 1-29 * the whole document *

DOI:   http://dx.doi.org/10.1038/mt.2008.200
 [AD]  - DANDE PRASAD ET AL, "Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2'-O-alkyl modifications", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 49, no. 5, doi:10.1021/JM050822C, ISSN 0022-2623, (20060309), pages 1624 - 1634, (20060208), XP002611368 [AD] 1-29 * abstract *

DOI:   http://dx.doi.org/10.1021/JM050822C
 [A]  - JONES G D ET AL, "DUPLEX- AND TRIPLEX-FORMING PROPERTIES OF 4'-THIO-MODIFIED OLIGODEOXYNUCLEOTIDES", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (19970520), vol. 7, no. 10, doi:10.1016/S0960-894X(97)00208-4, ISSN 0960-894X, pages 1275 - 1278, XP004136316 [A] 1-29 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0960-894X(97)00208-4
 [A]  - A HUTTENHOFER AND H.F. NOLLER, "Footprinting mRNA-ribosome complexes with chemical probes", THE EMBO JOURNAL, (19940101), vol. 13, no. 16, pages 3892 - 3901, XP055131438 [A] 1-29 * the whole document *
 [A]  - DEMESHKINA N ET AL, "Interactions of the ribosome with mRNA and tRNA", CURRENT OPINION IN STRUCTURAL BIOLOGY, ELSEVIER LTD, GB, vol. 20, no. 3, doi:10.1016/J.SBI.2010.03.002, ISSN 0959-440X, (20100601), pages 325 - 332, (20100412), XP027067342 [A] 1-29 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.sbi.2010.03.002
by applicantWO2010053572
 WO2011006810
 WO2011068810
 WO2012170930
 WO2012170889
    - YAMAMOTO, A. ET AL., EUR. J. PHARM., (2009), vol. 71, pages 484 - 489
    - DEBUS, H. ET AL., J. CONTROL REL., (2010), vol. 148, pages 334 - 343
    - M. KORMANN ET AL., NATURE BIOTECH., (2011), vol. 29, pages 154 - 159
    - K. KARIKO, MOLECULAR THERAPY, (2008), vol. 16, no. 11, pages 1833 - 1840
    - S. HOSHIKA ET AL., NUC. AC. RES. SUPP., (2003), vol. 3, pages 209 - 210
    - M. TAKAHASHI, M. ET AL., NUC. AC. RES., (2009), vol. 37, pages 1353 - 1362
    - DANDE ET AL., J. MED. CHEM., (2006), vol. 49, pages 1624 - 1634
    - HOSHIKA ET AL., NUC. AC. RES., (2004), vol. 32, pages 3815 - 3825
    - KATO ET AL., NUC. AC. RES., (2005), vol. 33, pages 2942 - 2951
    - MINAKAWA ET AL., BIOORG. MED. CHEM., (2008), vol. 16, pages 9450 - 9456
    - HUM. GENE THER., (2008), vol. 19, no. 9, pages 887 - 95
    - LASIC ET AL., TRENDS BIOTECHNOL., (1998), vol. 16, pages 307 - 321
    - DRUMMOND ET AL., PHARMACOL. REV., (1999), vol. 51, pages 691 - 743
    - HEYES ET AL., J. CONTR. REL., (2005), vol. 107, pages 276 - 287
    - SEMPLE ET AL., NATURE BIOTECH., (2010), vol. 28, pages 172 - 176
    - LOVE ET AL., PROC. NAT'L. ACAD. SCI., (2010), vol. 107, pages 1864 - 1869
    - FECHTER; BROWNLEE, J. GEN. VIROLOGY, (2005), vol. 86, pages 1239 - 1249
    - HEYES, J.; PALMER, L.; BREMNER, K.; MACLACHLAN, 1, "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J. CONTR. REL., (2005), vol. 107, doi:doi:10.1016/j.jconrel.2005.06.014, pages 276 - 287, XP008157522

DOI:   http://dx.doi.org/10.1016/j.jconrel.2005.06.014
    - SEMPLE, S.C. ET AL., "Rational Design of Cationic Lipids for siRNA Delivery", NATURE BIOTECH., (2010), vol. 28, doi:doi:10.1038/NBT.1602, pages 172 - 176, XP002633693

DOI:   http://dx.doi.org/10.1038/NBT.1602
    - LOVE, K.T. ET AL., "Lipid-like materials for low-dose in vivo gene silencing", PNAS, (2010), vol. 107, doi:doi:10.1073/pnas.0910603106, pages 1864 - 1869, XP055077922

DOI:   http://dx.doi.org/10.1073/pnas.0910603106
    - FECHTER, P.; BROWNLEE, G.G., "Recognition of mRNA cap structures by viral and cellular proteins", J. GEN. VIROLOGY, (2005), vol. 86, doi:doi:10.1099/VIR.0.80755-0, pages 1239 - 1249, XP002516933

DOI:   http://dx.doi.org/10.1099/VIR.0.80755-0
    - BOGACHEV, V.S., "Synthesis of deoxynucleoside 5'-triphosphates using trifluoroacetic anhydride as activation reagent", RUSS. J. BIOORG. CHEM., (1996), vol. 22, pages 599 - 604
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.